The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.
The report presents pipeline by Oncology indications. Key indications covered in this report include Esophageal Cancer Stomach Cancer, Colon Cancer, Pancreatic Cancer, Malignant Melanoma, Breast Cancer, Cervical Cancer, Ovary Cancer, Prostate Cancer, Renal Cancer, Bladder Cancer, Brain Cancer, Hodgkin’s disease, Acute Myeloid Leukemia and Multiple Myeloma.
By Clinical Trial Stages:
The report provides Oncology pipeline molecules by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.
By Drug Mechanism Classes:
The report provides Oncology pipeline molecules by their dominant drug mechanism class. This helps executives categorize molecules based on their drug class and also assess the strengths and weaknesses of compounds.
The report provides Oncology pipeline molecules by the developing company and the partnered company.
- Oncology Pipeline by Indication
- Oncology Pipeline by Clinical Trial Phase
- Oncology Pipeline by Drug Mechanism Classes
- Oncology Pipeline by Company